dc.contributor.author | Director, Moderna Medical | |
dc.date.accessioned | 2021-07-22T20:09:37Z | |
dc.date.available | 2021-07-22T20:09:37Z | |
dc.date.issued | 2017 | |
dc.identifier.uri | https://clinicaltrials.gov/ct2/show/NCT03014089 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/2630 | |
dc.description.abstract | The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects. Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Prevention
Official Title: A Phase 1/2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region | en_US |
dc.language | English | en_US |
dc.subject | Zika Research Project | en_US |
dc.subject | Vaccine | en_US |
dc.subject | Zika Virus | en_US |
dc.subject | immunogenicity | en_US |
dc.subject | United States | en_US |
dc.title | Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects | en_US |
eihealth.country | Others | en_US |
eihealth.category | Epidemiology and epidemiological studies | en_US |
eihealth.type | Other publications | en_US |
eihealth.maincategory | Protect Health Care Workers / Proteger la Salud de los Trabajadores | en_US |
dc.relation.ispartofjournal | Clinical Trials | en_US |
dc.contributor.corporatename | Moderna Therapeutics, Biomedical Advanced Research and Development Authority | en_US |